Results 191 to 200 of about 41,600 (260)

Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice (CombiKid Study)

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7950-7963, September 2026.
ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton, Mark Joy, Anna K. Forbes, Martin B. Whyte, José M. Ordóñez‐Mena, Xuejuan Fan, Filipa Ferreira, Bernardo Meza‐Torres, Neil Munro, Simon de Lusignan, David C. Wheeler, Michael D. Feher   +11 more
wiley   +1 more source

A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor. [PDF]

Cureus
Fukata M, Omura T, Maeda K, Mori T, Kato H, Kuzuya M.   +5 more
europepmc   +1 more source

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant‐Level Exploratory Analysis of the Randomised CONFIDENCE Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7964-7973, September 2026.
ABSTRACT Aims This prespecified analysis evaluated whether the safety and efficacy of finerenone and a sodium–glucose cotransporter 2 inhibitor (SGLT2i) combination vary by baseline glycated haemoglobin (HbA1c). Materials and Methods Adults with type 2 diabetes and a urinary albumin‐to‐creatinine ratio (UACR) of 100 − < 5000 mg/g, estimated glomerular ...
Janet B. McGill, Jennifer B. Green, Hiddo J. L. Heerspink, Johannes F. E. Mann, Amy K. Mottl, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Masaomi Nangaku, Meike Brinker, Charlie Scott, Katja Rohwedder, Li Li, Na Li, Margarida Seco, Rajiv Agarwal   +15 more
wiley   +1 more source

Association of urinary dipeptidyl peptidase 4 activity with clinical outcomes in people with chronic kidney disease. [PDF]

Sci Rep
Benetti A, Ribeiro-Silva JC, Gómez LM, Tavares CAM, Bensenor IJ, Lotufo PA, Titan SMO, Girardi ACC.   +7 more
europepmc   +1 more source

Subgroups of Adult‐Onset Diabetes: A Prospective Follow‐Up Study of Progression of Insulin Resistance and Deficiency and Association With Liver Steatosis and Fibrosis

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8004-8015, September 2026.
ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen, Annemari Käräjämäki, Aki J. Käräjämäki, Samu Kurki, Liisa Hakaste, Olof Asplund, Johan Hultman, Kaj Lahti, Mikko Lehtovirta, Emma Ahlqvist, Tiinamaija Tuomi   +10 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8482-8493, September 2026.
ABSTRACT Aims We evaluated the risk of mental health disorders among glucagon‐like peptide‐1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. Materials and Methods We conducted a nationwide, active‐comparator new‐user cohort study using the Korean ...
Chungsoo Kim, Seonji Kim, Dong Yun Lee, Eugene Han, Yong‐ho Lee, Seng Chan You   +5 more
wiley   +1 more source

Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors.

JAMA Netw Open
Turchin A, Petito LC, Hegermiller E, Carnahan R, DeVries A, Goel S, Lansang MC, McDonnell ME, Nair V, Priest E, Willey VJ, Kaul AF, Hernán MA.   +12 more
europepmc   +1 more source

Cardiovascular and renal outcomes of sodium-glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes post-PCI: a meta-analysis of 14,511 patients. [PDF]

Diabetol Metab Syndr
Badran AS, Gbreel MI, Tawfik AM, Balata M.   +3 more
europepmc   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8172-8188, September 2026.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

DPPPRED-IV: An Ensembled QSAR-Based Web Server for the Prediction of Dipeptidyl Peptidase 4 Inhibitors. [PDF]

Int J Mol Sci
Carpio LE, Olivares M, Ortega-Vallbona R, Serrano-Candelas E, Sanz Y, Gozalbes R.   +5 more
europepmc   +1 more source